Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older. In addition, the company develops Enfortumab vedotin, ADC composed of an anti-Nectin-4 monoclonal antibody to treat bladder cancer, and ovarian and lung cancers; Tucatinib, an oral tyrosine kinase inhibitor for HER2-positive metastatic breast cancer; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. Further, it develops early-stage clinical product candidates comprising ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SGN-CD48A; SEA-BCMA for patients with relapsed or refractory multiple myeloma; and SGN-2FF for patients with advanced solid tumors. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Progenics Pharmaceuticals Inc.; Unum Therapeutics, Inc.; Pieris Pharmaceuticals, Inc.; Pieris Pharmaceuticals AG; Takeda Pharmaceutical Company Limited; Astellas Pharma, Inc.; and Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone425-527-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$654.70 million
Profitability
Miscellaneous
Employees1,302
OptionableOptionable
Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions
What is Seattle Genetics' stock symbol?
Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."
How were Seattle Genetics' earnings last quarter?
Seattle Genetics, Inc. (NASDAQ:SGEN) announced its earnings results on Thursday, February, 7th. The biotechnology company reported ($0.75) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.36. The biotechnology company earned $174.50 million during the quarter, compared to the consensus estimate of $164.03 million. Seattle Genetics had a negative return on equity of 19.33% and a negative net margin of 34.01%. The company's revenue was up 34.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.41) earnings per share. View Seattle Genetics' Earnings History.
When is Seattle Genetics' next earnings date?
What guidance has Seattle Genetics issued on next quarter's earnings?
Seattle Genetics issued an update on its FY 2019 earnings guidance on Thursday, February, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $790-840 million, compared to the consensus revenue estimate of $864.94 million.
What price target have analysts set for SGEN?
13 brokers have issued 12 month price targets for Seattle Genetics' shares. Their forecasts range from $50.00 to $101.00. On average, they anticipate Seattle Genetics' share price to reach $80.70 in the next year. This suggests a possible upside of 12.9% from the stock's current price. View Analyst Price Targets for Seattle Genetics.
What is the consensus analysts' recommendation for Seattle Genetics?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seattle Genetics in the last year. There are currently 1 sell rating, 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seattle Genetics.
What are Wall Street analysts saying about Seattle Genetics stock?
Here are some recent quotes from research analysts about Seattle Genetics stock:
- 1. HC Wainwright analysts commented, "We reach a price target of $98 after adjusting new corporate tax rate, cash, and other program updates. The price target is based on a sum-of-parts NPV-DCF ($63.2 HL + $3.6 relapsed sALCL+ $11.2 frontline PTCL + $17.7 platform + $2.9 cash). Key risks to achievement of our target price include trial failures, safety issues, regulatory delays, competition, and dilutive financing. Seattle Genetics Inc. February 8, 2019 H.C. WAINWRIGHT & CO. EQUITY RESEARCH 2Seattle Genetics, Inc." (2/8/2019)
- 2. According to Zacks Investment Research, "Seattle Genetics' sole marketed drug, Adcetris, is performing well since its launch. The label expansion in frontline Hodgkin lymphoma, pcALCL, CD30-expressing MF and T-cell lymphoma is encouarging. The FDA approval of Adcetris in combination with chemotherapy for the treatment of stage III or IV classical Hodgkin lymphoma (cHL) and peripheral T-cell lymphomas (PTCL) will further boost sales. The company’s collaboration with Takeda development/commercialization of Adcetris shows promise. However, its heavy dependence solely on Adcetris for growth has its inherent risks. Though the company has multiple candidates in its pipeline, most are in early stages of development. Shares of the company have outperformed the industry in 2018. Estimates looks stable ahead of the Q4 earnings release. Seattle Genetics has a positive record of earnings surprises in recent quarters." (1/30/2019)
- 3. JPMorgan Chase & Co. analysts commented, "With SGEN’s recent strength (up ~50% over the last 3 mos), we’ve been asked frequently – what would we need to see from Adcetris to maintain this momentum? In our view, this question should be more than adequately answered following a big beat this quarter with Adcetris sales coming in at $122.4M vs guidance of $105-110M and consensus of $107M. Additionally, management provided 3Q guidance of $130-135M vs cons of $115M. Coupled with continued pipeline progress (completion of enrollment in the pivotal cohort of EV-201 and first patient dosed in innovaTV 204/207, as previously disclosed), as well as narrowing of guidance for E-2 (now early 4Q18) we see this as another productive quarter on many fronts." (7/27/2018)
Has Seattle Genetics been receiving favorable news coverage?
News stories about SGEN stock have been trending somewhat positive recently, InfoTrie reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Seattle Genetics earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days.
Who are some of Seattle Genetics' key competitors?
Some companies that are related to Seattle Genetics include NOVOZYMES A/S/S (NVZMY), Qiagen (QGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), BIO-TECHNE (TECH), argenx (ARGX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Spark Therapeutics (ONCE), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN) and Aerie Pharmaceuticals (AERI).
Who are Seattle Genetics' key executives?
Seattle Genetics' management team includes the folowing people:
- Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 58)
- Mr. Todd E. Simpson, Chief Financial Officer (Age 58)
- Dr. Vaughn B. Himes, Chief Technology Officer (Age 58)
- Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 51)
- Dr. Jonathan G. Drachman, Strategic Advisor for Innovation (Age 57)
Who are Seattle Genetics' major shareholders?
Seattle Genetics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.69%), Baillie Gifford & Co. (4.19%), First Trust Advisors LP (1.26%), Manning & Napier Group LLC (1.02%), Frontier Capital Management Co. LLC (0.73%) and Geode Capital Management LLC (0.70%). Company insiders that own Seattle Genetics stock include Bros Advisors Lp Baker, Clay B Siegall, Darren S Cline, David W Gryska, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.
Which institutional investors are selling Seattle Genetics stock?
SGEN stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., D. E. Shaw & Co. Inc., Two Sigma Advisers LP, Los Angeles Capital Management & Equity Research Inc., Bank of America Corp DE, Tekla Capital Management LLC, TD Asset Management Inc. and Pinnacle Associates Ltd.. Company insiders that have sold Seattle Genetics company stock in the last year include Clay B Siegall, Darren S Cline, David W Gryska, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.
Which institutional investors are buying Seattle Genetics stock?
SGEN stock was acquired by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, First Trust Advisors LP, Amundi Pioneer Asset Management Inc., Manning & Napier Group LLC, Sectoral Asset Management Inc, Geode Capital Management LLC, BlackRock Inc. and Rhenman & Partners Asset Management AB. View Insider Buying and Selling for Seattle Genetics.
How do I buy shares of Seattle Genetics?
Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Seattle Genetics' stock price today?
One share of SGEN stock can currently be purchased for approximately $71.48.
How big of a company is Seattle Genetics?
Seattle Genetics has a market capitalization of $11.48 billion and generates $654.70 million in revenue each year. The biotechnology company earns $-222,690,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Seattle Genetics employs 1,302 workers across the globe.
What is Seattle Genetics' official website?
How can I contact Seattle Genetics?
Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]
MarketBeat Community Rating for Seattle Genetics (NASDAQ SGEN)
MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe SGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
